Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 05 2022
16 05 2022
Historique:
received:
06
08
2021
accepted:
22
04
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
20
5
2022
Statut:
epublish
Résumé
We show how the use and interpretation of population-based cancer survival indicators can help oncologists talk with breast cancer (BC) patients about the relationship between their prognosis and their adherence to endocrine therapy (ET). The study population comprised a population-based cohort of estrogen receptor positive BC patients (N = 1268) diagnosed in Girona and Tarragona (Northeastern Spain) and classified according to HER2 status (+ / -), stage at diagnosis (I/II/III) and five-year cumulative adherence rate (adherent > 80%; non-adherent ≤ 80%). Cox regression analysis was performed to identify significant prognostic factors for overall survival, whereas relative survival (RS) was used to estimate the crude probability of death due to BC (P
Identifiants
pubmed: 35577853
doi: 10.1038/s41598-022-12228-y
pii: 10.1038/s41598-022-12228-y
pmc: PMC9110408
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8097Informations de copyright
© 2022. The Author(s).
Références
Epidemiology. 2013 May;24(3):454-60
pubmed: 23493031
CA Cancer J Clin. 2020 Sep;70(5):355-374
pubmed: 32813307
Ann Oncol. 2019 Nov 1;30(11):1784-1795
pubmed: 31591636
Int J Epidemiol. 2020 Oct 1;49(5):1517-1525
pubmed: 32984907
BMC Cancer. 2019 Mar 14;19(1):230
pubmed: 30871490
Clin Transl Oncol. 2018 Oct;20(10):1252-1260
pubmed: 29511947
Breast Care (Basel). 2021 Apr;16(2):135-143
pubmed: 34002112
Breast. 2020 Oct;53:172-180
pubmed: 32836201
Breast Cancer Res. 2021 Feb 1;23(1):17
pubmed: 33526044
Ann Oncol. 2015 Sep;26 Suppl 5:v8-30
pubmed: 26314782
Breast Cancer Res Treat. 2020 Jan;179(1):217-227
pubmed: 31571072
J Clin Oncol. 2017 Sep 20;35(27):3113-3122
pubmed: 28654365
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Int J Cancer. 2019 Mar 15;144(6):1251-1261
pubmed: 30367449
Patient Prefer Adherence. 2018 May 22;12:887-897
pubmed: 29872274
Gynecol Oncol. 2013 Sep;130(3):609-14
pubmed: 23747837
Br J Cancer. 2012 Oct 9;107(8):1249-56
pubmed: 22955858
Breast Cancer Res Treat. 2019 Sep;177(2):497-505
pubmed: 31168758
Clin Breast Cancer. 2015 Oct;15(5):381-9
pubmed: 25861716
Methods Mol Biol. 2020;2204:53-61
pubmed: 32710314
Breast. 2005 Dec;14(6):452-7
pubmed: 16198110
Br J Cancer. 2008 Dec 2;99(11):1763-8
pubmed: 18985046
J Breast Cancer. 2019 Mar 11;22(1):86-95
pubmed: 30941236
Breast Cancer Res Treat. 2020 Jun;181(2):339-345
pubmed: 32253684
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Oncol Pract. 2013 Jul;9(4):e136-40
pubmed: 23942930
Breast Cancer Res Treat. 2010 Jul;122(2):591-600
pubmed: 20063196
Ann Surg Oncol. 2015 Apr;22(4):1102-10
pubmed: 25249260
Ann Oncol. 2013 Feb;24(2):355-361
pubmed: 23028039
J Clin Oncol. 2001 Feb 15;19(4):980-91
pubmed: 11181660
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Support Care Cancer. 2020 Nov;28(11):5075-5084
pubmed: 32601852
Eur J Cancer. 2006 May;42(8):1143-50
pubmed: 16644204
Stat Med. 2010 Mar 30;29(7-8):885-95
pubmed: 20213719
Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626
pubmed: 29593010
Breast. 2015 Feb;24(1):62-7
pubmed: 25486877
Int J Cancer. 2013 May 15;132(10):2404-12
pubmed: 23047687
Breast Cancer Res Treat. 2016 Sep;159(2):293-303
pubmed: 27492739
Breast Cancer Res Treat. 2019 Jun;175(3):733-740
pubmed: 30887164
Ann Transl Med. 2020 Apr;8(8):544
pubmed: 32411767
Ann Oncol. 2020 Jun;31(6):674-696
pubmed: 32199930
Clin Transl Oncol. 2019 Aug;21(8):1014-1025
pubmed: 30607790
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Value Health. 2008 Jan-Feb;11(1):44-7
pubmed: 18237359
N Engl J Med. 2005 Dec 29;353(26):2747-57
pubmed: 16382061
Medicine (Baltimore). 2015 Jul;94(26):e1071
pubmed: 26131828
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
J Clin Oncol. 2016 Jul 20;34(21):2452-9
pubmed: 27217455
Lancet. 2005 Jan 1-7;365(9453):60-2
pubmed: 15639680
Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):953-9
pubmed: 27125337
Br J Cancer. 2019 Nov;121(10):883-889
pubmed: 31601960
Cancer Treat Rev. 2021 Nov;100:102264
pubmed: 34388473
Clin Transl Oncol. 2021 Jul;23(7):1377-1385
pubmed: 33517542
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
J Clin Oncol. 2014 Jan 20;32(3):238-50
pubmed: 24344212
Clin Transl Oncol. 2018 Feb;20(2):201-211
pubmed: 28718071
BMC Cancer. 2018 Aug 2;18(1):781
pubmed: 30068302